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In December 2009, claiming priority from an earlier US patent 
application filed in December 2008, the Californian direct-to-
consumer genetic testing company 23andMe filed US Patent 
Application Serial No. 12/592950. A Notice of Allowance for 
this case was issued by the US Patent and Trademark Office 
in June 2013, and it will issue as US Patent No. 8543339 on 
24  September 2013. It contains claims to a computer system 
and to a computer program, but our focus here is on the patent’s 
claims to a method for gamete donor selection:
“A method for gamete donor selection,1 comprising (i) receiv-
ing a specification including a phenotype of interest that can be 
present in a hypothetical offspring; (ii) receiving a genotype of 
a recipient and a plurality of genotypes of a respective plurality 
of donors; (iii) using one or more computer processors coupled 
to one or more memories configured to provide one or more 
computer processors with instructions to determine statistical 
information including probabilities of observing the phenotype 
of interest resulting from different combinations of the geno-
type of the recipient and genotypes of the plurality of donors; 
and (iv) identifying a preferred donor among the plurality of 
donors, based at least in part on the statistical information 
determined, including comparing the probabilities of observ-
ing the phenotype of interest resulting from different combina-
tions of the genotype of the recipient and the genotypes of the 
plurality of donors to identify the preferred donor.”
Taken out of “patentese,” what 23andMe is claiming is a 
method by which prospective donors of ova and/or sperm 
may be selected so as to increase the likelihood of producing 
a human baby with characteristics desired by the prospective 
parents, the selection being based on a computerized compari-
son of the genotypic data of the egg provider with that of the 
sperm provider. The phenotypic characteristics that may be 
on the users’ (e.g., parents’) “shopping list” can include both 
disease-related and non–disease-related traits, such as height, 
eye color, muscle development, personality characteristics, and 
risks of developing age-related macular degeneration or cer-
tain types of cancer.2 Figure 4 of the patent application lists the 
following alternative choices: “I prefer a child with”: “longest 
expected life span”/“least expected life cost of health care”/“least 
expected cumulative duration of hospitalization.” Figure 6 visu-
alizes a choice between the “offspring’s possible traits” of “0% 
likely endurance athlete” and “100% likely sprinter.”2 Of note, 
sex is also mentioned as an example of the phenotypic char-
acteristics. 23andMe’s claim is extremely broad insofar as it 
concerns “selection” for any phenotypic trait, which of course 
includes polygenetic traits that might be more than a bit dif-
ficult to select for; however, in 23andMe’s favor, we must point 
out that what is claimed is not a cast-iron, fool-proof method 
 guaranteeing that the eventual child will have all the pheno-
typic traits on the parents’ shopping list, an impossible task, but 
merely a method of improving the chances that the baby has the 
“right” characteristics.
It has been said that taking out a patent on a technology 
that one disapproves of provides a further way, beyond that of 
statute law, to prevent others from adopting it for a while. For 
example, in 1997, Stuart Newman and Jeremy Rifkin filed a US 
patent application directed to human/animal chimeras. Stuart 
Newman opposed patents on living things. “[H]e had no inten-
tion of making the creatures. His goal was to set a legal prec-
edent that would keep others from profiting from any similar 
‘inventions.’”3,4 However, there is no indication that this is the 
rationale behind the case discussed in this commentary.
Moreover, at no stage during the examination of the patent 
application did the patent office Examiner question whether 
techniques for facilitating the “design” of future human babies 
were appropriate subject matter for a patent (http://portal.uspto.
gov/pair/PublicPair, patent application number 12/592950). It 
might be argued that this is not surprising—unlike the patent 
law operating across Europe (the European Patent Convention, 
or EPC), US patent law contains no explicit clause excluding 
from patent-eligibility inventions that contravene morality. 
Yet the utility requirement of US patent law includes a moral-
ity aspect which, admittedly, is very rarely applied by the US 
Patent and Trademark Office, but which was, for example, 
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invoked when the human/animal chimera patent application 
mentioned above was rejected. In a press release, the US Patent 
and Trademark Office explained that: “[T]he courts have inter-
preted the utility requirement to exclude inventions deemed 
to be “injurious to the well-being, good policy, or good mor-
als of society.” … [I]nventions directed to human/nonhuman 
chimera could, under certain circumstances, not be patentable 
because, among other things, they would fail to meet the pub-
lic policy and morality aspects of the utility requirement.”5 This 
raises the interesting speculation as to whether the US Patent 
and Trademark Office might have considered objecting to 
23andMe’s patent claims as injurious to morality and the well-
being of the society.
Although we cannot address that question here, we should 
like to note that the genetic selection of children has been advo-
cated by philosophers such as Savulescu and Kahane,6 who 
argue that prospective parents would “aim to have the child 
who, given his/her genetic endowment, can be expected to 
enjoy most well-being in his/her life.” They emphasize that this 
includes the selection of both non–disease-related and disease-
related characteristics. Others, such as Sandel,7 argue against it 
on the basis that it indicates that the parents have undesirable 
attitudes that are at odds with the norm of unconditional love 
for one’s child: “The problem lies in the hubris of the design-
ing parents.” He makes it clear that his objections concern the 
selection of non–disease-related traits: “To appreciate children 
as gifts or blessings is not to be passive in the face of illness 
or disease … In caring for the health of their children, parents 
do not cast themselves as designers or convert their children 
into products of their will or instruments of their ambition. The 
same cannot be said of parents … who aspire to bioengineer 
their child’s intellectual endowments or athletic prowess.”7
Again, we cannot elaborate here on this debate,8 but it is 
clear that selecting children in ways such as those patented by 
23andMe is hugely ethically controversial. The use of preim-
plantation genetic diagnosis to avoid implantation of embryos 
bearing serious genetic abnormalities is by now becoming 
commonplace, but a computerized process for selecting gamete 
donors to achieve a baby with a “phenotype of interest” that the 
prospective parent “desires in his/her hypothetical offspring,” 
as 23andMe puts it,2 seems to have much broader implications, 
for this process also entails the selection of traits that are not 
disease related.
What makes this case even more surprising is the fact that 
23andMe is no stranger to controversy regarding its patenting 
activities. In the days following its May 2012 announcement9 
on the company blog that it was to be granted a US patent for 
a test for propensity to develop Parkinson disease, the blog was 
filled with reactions of upset customers, the providers of the 
genetic and phenotypic data which constitutes 23andMe’s bio-
bank.10 Since 23andMe is a commercial entity, clearly intended 
to bring profit to its investors at some stage at least, its attempts 
to seek patents are not surprising. Moreover, such attempts 
are not inherently problematic. However, for a company that 
invites audience participation, and so needs customers and 
their goodwill to maintain and expand its most valuable asset, 
i.e., its biobank, it is surprising that, following the uproar that 
greeted the announcement of its Parkinson disease patent, 
23andMe has pursued this patent with no apparent public dis-
cussion. For instance, do the consumers who have also allowed 
23andMe to use their genotypic data for the research conducted 
by the company agree with the use of their information for 
the purpose of developing a method for gamete donor selec-
tion? Public trust is central to the continuing success of human 
genetics research in general and biobank-based research in par-
ticular. We urge maximal transparency by all engaged in human 
genetics research.
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